Quick Answer
Kymera Therapeutics, Inc. reported Stockholders Equity of $1.58 billion for the year ending 2025.
- Kymera Therapeutics, Inc. showed an increase of +89.0% in Stockholders Equity from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$52.08 million | Q3 2019: -$63.22 million | Q1 2020: -$93.80 million | Q2 2020: -$107.29 million | Q3 2020: $294.69 million | Q1 2021: $275.25 million | Q2 2021: $258.10 million | Q3 2021: $483.14 million | Q1 2022: $428.72 million | Q2 2022: $397.95 million | Q3 2022: $512.89 million | Q1 2023: $462.01 million | Q2 2023: $435.43 million | Q3 2023: $395.54 million | Q1 2024: $711.20 million | Q2 2024: $684.92 million | Q3 2024: $892.93 million | Q1 2025: $786.23 million | Q2 2025: $971.48 million | Q3 2025: $946.26 million.
- Over the full 8 years of available data (2018 to 2025), Kymera Therapeutics, Inc.'s Stockholders Equity has grown by 4,687.2%.
- Historical annual values: Fiscal year 2025: $1.58 billion | Fiscal year 2024: $835.62 million | Fiscal year 2023: $394.97 million | Fiscal year 2022: $490.15 million | Fiscal year 2021: $459.64 million | Fiscal year 2020: $283.89 million | Fiscal year 2019: -$74.41 million | Fiscal year 2018: -$34.44 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: